Intracellular Trafficking of AAV5 Vectors

被引：1
|
作者：
Balakrishnan, Balaji [1 ,2 ]
Jayandharan, Giridhara R. [1 ,2 ]
机构：
[1] Christian Med Coll & Hosp, Dept Hematol, Vellore 632004, Tamil Nadu, India
[2] Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India
来源：
HUMAN GENE THERAPY METHODS | 2016年 / 27卷 / 02期
关键词：
ADENOASSOCIATED VIRUS; PATHWAY;
D O I：
10.1089/hgtb.2016.020
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The present study was designed to visualize the cellular trafficking of adeno-associated virus (AAV) vectors in general and AAV5 serotype vectors in particular. We fluorescently labeled AAV5 wild-type and a mutant (S652A) virus and studied their infection process by live cell imaging and confocal microscopy. Our data demonstrate considerable difference in the ability of these vectors to reach the nuclear compartment within the first 6 hr after infection.
引用
收藏
页码：47 / 48
页数：2
相关论文
共 50 条
  • [31] Identification and Mutagenesis of the AAV5 Sialic Acid Binding Region
    Afione, Sandra
    DiMattia, Michael A.
    Halder, Sujata
    Di Pasquale, Giovanni
    Agbandje-McKenna, Mavis
    Chiorini, John
    MOLECULAR THERAPY, 2015, 23 : S39 - S39
  • [32] Intracellular trafficking of hybrid gene delivery vectors
    Keswani, Rahul K.
    Lazebnik, Mihael
    Pack, Daniel W.
    JOURNAL OF CONTROLLED RELEASE, 2015, 207 : 120 - 130
  • [33] Intracellular trafficking of retroviral vectors: obstacles and advances
    Anderson, JL
    Hope, TJ
    GENE THERAPY, 2005, 12 (23) : 1667 - 1678
  • [34] Intracellular trafficking of retroviral vectors: obstacles and advances
    J L Anderson
    T J Hope
    Gene Therapy, 2005, 12 : 1667 - 1678
  • [35] Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3-Mutant Dogs
    Ye, Guo-jie
    Komaromy, Andras M.
    Zeiss, Caroline
    Calcedo, Roberto
    Harman, Christine D.
    Koehl, Kristin L.
    Stewart, Gabriel A.
    Iwabe, Simone
    Chiodo, Vince A.
    Hauswirth, William W.
    Aguirre, Gustavo D.
    Chulay, Jeffrey D.
    HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2017, 28 (04) : 197 - 207
  • [36] Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero
    Lipshutz, GS
    Titre, D
    Brindle, M
    Bisconte, AR
    Contag, CH
    Gaensler, KML
    MOLECULAR THERAPY, 2003, 8 (01) : 90 - 98
  • [37] Comparison of AAV2 and AAV5 in gene transfer in the injured spinal cord of mice
    Peng, Su-Ping
    Kuegler, Sebastian
    Ma, Zhi-Kui
    Shen, Yan-Qin
    Schachner, Melitta
    NEUROREPORT, 2011, 22 (12) : 565 - 569
  • [38] Circulating Anti-AAV5 Neutralizing Antibody Titers up to 1:1031 Do Not Affect Liver Transduction Efficacy of AAV5 Vectors in Non-Human Primates
    Majowicz, Anna
    Spronck, Lisa
    de Haan, Martin
    Petry, Harald
    Nijmeijer, Bart
    Ferreira, Valerie
    MOLECULAR THERAPY, 2017, 25 (05) : 94 - 94
  • [39] Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells
    Handyside, Britta
    Ismail, Ashrafali Mohamed
    Zhang, Lening
    Yates, Bridget
    Xie, Lin
    Sihn, Choong-Ryoul
    Murphy, Ryan
    Bouwman, Taren
    Kim, Chan Kyu
    De Angelis, Rolando
    Karim, Omair A.
    McIntosh, Nicole L.
    Doss, Michael Xavier
    Shroff, Shilpa
    Pungor, Erno
    Bhat, Vikas S.
    Bullens, Sherry
    Bunting, Stuart
    Fong, Sylvia
    MOLECULAR THERAPY, 2022, 30 (12) : 3570 - 3586
  • [40] Viral vectors based on AAV2 and AAV5 serotypes display disparate transduction patterns and efficiencies in specific anatomical regions of the central nervous system.
    Burger, C
    Gorbakyuk, O
    Velardo, MJ
    Peden, C
    Williams, P
    Zolotukhin, S
    Reier, PJ
    Muzyczka, N
    Mandel, RJ
    EXPERIMENTAL NEUROLOGY, 2003, 181 (01) : 87 - 87
12345